Epidemiological characteristics, underlying diseases and treatments of elderly hospitalized patients with pneumonia

doi:10.3969/j.issn.1004-583X.2021.03.008

Abstract

Abstract:

Objective To investigate underlying diseases, etiological characteristics and treatments in elderly hospitalized patients with community-acquired pneumonia (CAP), and analyze the factors related to the length of hospital stay of the patients. Methods A total of 400 CAP patients who were hospitalized in our hospital were enrolled and assigned into the elderly group(n=274, ages ≥65 years old) and the non-elderly group(n=126, ages <65 years old) by age. The underlying diseases, etiological characteristics and treatment measures of the two groups were compared, and the influencing factors of the length of hospital stay in the elderly group were analyzed by Logistic regression. Results The indicators of hypertension (35.04%), diabetes (20.44%), coronary heart disease (12.04%), chronic heart failure (9.85%), chronic obstructive pulmonary disease (COPD)(15.69%), and chronic kidney disease (12.41%) of the elderly group were all higher than those of the non-elderly group(P<0.05). The indicators of bacteria (28.83%) and fungi (18.98%) infection in the elderly group were higher than those in the non-elderly group (P<0.05). The proportion of patients with 2 pathogens detected in the elderly group (16.06%) was higher than that in the non-elderly group (P<0.05); Multivariate Logistic analysis showed that, ages≥80 years old (OR=6.477), complicated malignant tumors (OR=8.642), complicated chronic heart failure (OR=14.625), glucocorticoid treatment (OR=6.729) were the independent influencing factors of the length of hospital stay of the elderly patients with CAP (P<0.05). Conclusion Most elderly patients with CAP were associated with a variety of underlying diseases, and elderly (ages ≥80 years old), complicated malignant tumors, complicated chronic heart failure, use of glucocorticoids are independent factors influencing the length of hospital stay.

Key words: pneumonia, elderly, pathogens, length of hospital stay, epidemiology

CLC Number:

R563.1

Cai Mujing, Chen Jingjing, Huang Rukun, Cai Xiaoni, Zheng Ruoxian. Epidemiological characteristics, underlying diseases and treatments of elderly hospitalized patients with pneumonia[J]. Clinical Focus, 2021, 36(3): 229-232.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.03.008

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I3/229

Figures/Tables 7

References 21

[1]	Cataudella E, Giraffa CM, Di Marca S, et al. Neutrophil-to- lyinphocyte ratio:an enierging marker predicting prognosis in elderly adults with eomnmnity-acquired pneumonia[J]. J Am Geriatr Soc, 2017,65(8):1796-1801. doi: 10.1111/jgs.14894 pmid: 28407209
[2]	Viasus D, Nfifiez-Ramos JA, Viloria SA, et al. Pharmacotherapy for community-acquired pneumonia in the elderly[J]. Expert Opin Pharmaeo, 2017,18(10):957-964.
[3]	Amalakuhan B, Eehevarria KL, Restrepo MI. Managing community acquired pneumonia in the elderly--the next generation of pharmacotherapy on the horizon[J]. Expert Opin Pharmaeo, 2017,18(11):1039-1048.
[4]	Xiao HL, Xin L, Wang Y, et al. Establishment of a predictive diagnostic model for acute mycoplasma pneumoniae infection in elderly patients with community-acquired pneunlonia[J]. Bionled Environ Sci, 2017,30(7):540-544.
[5]	靳淑雁, 李双飞, 郑静等. 深圳市成人住院社区获得性肺炎流行病学特征分析[J]. 预防医学情报杂志, 2017,33(7):693-698.
[6]	中华医学会, 中华医学会杂志社, 中华医学会全科医学分会等. 成人社区获得性肺炎基层诊疗指南(2018年)[J]. 中华全科医师杂志, 2019,18(2):117-126.
[7]	Ahuna VS, Aliaga VR, Maguifia JL, et al. Risk of comnmnity-acquired pneumonia in oldeI adults with sarcopenia of a hospital from Callao,Peru 2010-2015[J]. Arch Gerontol Geriatr, 2019,82:100-105. doi: 10.1016/j.archger.2019.01.008 URL
[8]	Garin N, Marti C, Scheffler M, et al. Computed tomography scan contribution to the diagnosis of comniunity-acquired pneu-- monia[J]. Curr Opin Puhn Med, 2019,25(3):242-248.
[9]	马江伟, 毕钰, 何丽艳等. 社区获得性肺炎临床特点分析[J]. 中国医科大学学报, 2020,49(1):1-5.
[10]	Violi F, Cangemi R, Falcone M, et al. Cardiovascular Complications and Short-term mortality risk in community-acquired pneumonia[J]. Clin Infect Dis, 2017,64(11):1486-1493. doi: 10.1093/cid/cix164 URL
[11]	崔佳佳. 老年社区获得性肺炎患者死亡的影响因素分析[D]. 新乡医学院, 2017.
[12]	刘宇智, 金宁, 张潭军等. 重症社区获得性肺炎病原微生物调查和预后因素分析[J]. 临床肺科杂志, 2017,22(9):1574-1576.
[13]	叶青, 王笑灵, 田国保等. 儿童及成人重症社区获得性肺炎病原学及流行病学研究[J]. 临床和实验医学杂志, 2019,18(11):1169-1172.
[14]	黄嘉炜, 肖琴, 吴建勇等. 广州市中老年社区获得性肺炎住院患者特征及住院时长的影响因素研究[J]. 中华流行病学杂志, 2017,38(4):542-546.
[15]	曹孟孟, 朱华栋. 老年社区获得性肺炎的临床特征及诊疗进展[J]. 中国急救医学, 2020,40(3):268-273.
[16]	Emshaty W, Mashaly M, Moawad A, et al. Diagnostic value of neutrophillymphocyte ratio versus C-reactive protein in discrimination between different pathogens causing community- acquired pneunlonia[J]. Comparat Clin Pathol, 2017,26:757-765.
[17]	Cillóniz C, Rodríguez-Hurtado D, Torres A. Characteristics and management of community-acquired pneumonia in the era of global aging[J]. Med Sci(Basel), 2018,6(2):35.
[18]	李丽娟, 刘颖梅, 王一民等. 糖皮质激素长期应用宿主合并社区获得性肺炎的临床特征及预后分析[J]. 中华医学杂志, 2018,98(10):738-743.
[19]	武芳芳, 李爱民, 瞿奥林等. 社区获得性肺炎相关心血管事件的研究进展[J]. 国际呼吸杂志, 2019,39(10):793-796.
[20]	杨扬, 游曼清, 罗林城等. 老年社区获得性肺炎患者预后的影响因素研究[J]. 实用心脑肺血管病杂志, 2019,27(9):35-38.
[21]	郑金丹, 李琪, 陈志林等. 影响高龄重症社区获得性肺炎患者预后的相关危险因素分析[J]. 中国中西医结合急救杂志, 2019,26(5):551-555.

组别	例数	性别[例(%)]		年龄 (岁)	吸烟史 [例(%)]	饮酒史 [例(%)]	居住地为城镇 [例(%)]	付费方式为医保 [例(%)]
组别	例数	男	女	年龄 (岁)	吸烟史 [例(%)]	饮酒史 [例(%)]	居住地为城镇 [例(%)]	付费方式为医保 [例(%)]
老年组	274	162(59.12)	112(40.88)	67.32±6.85	103(37.59)	26(9.49)	202(73.72)	253(92.34)
非老年组	126	79(62.70)	47(37.30)	56.59±5.27	44(34.92)	13(10.32)	95(75.40)	118(93.65)
t/χ²值		0.460		15.586	0.265	0.067	0.127	0.222
P值		0.497		<0.01	0.607	0.795	0.722	0.638

组别	例数	性别[例(%)]		年龄 (岁)	吸烟史 [例(%)]	饮酒史 [例(%)]	居住地为城镇 [例(%)]	付费方式为医保 [例(%)]
组别	例数	男	女	年龄 (岁)	吸烟史 [例(%)]	饮酒史 [例(%)]	居住地为城镇 [例(%)]	付费方式为医保 [例(%)]
老年组	274	162(59.12)	112(40.88)	67.32±6.85	103(37.59)	26(9.49)	202(73.72)	253(92.34)
非老年组	126	79(62.70)	47(37.30)	56.59±5.27	44(34.92)	13(10.32)	95(75.40)	118(93.65)
t/χ²值		0.460		15.586	0.265	0.067	0.127	0.222
P值		0.497		<0.01	0.607	0.795	0.722	0.638

组别	例数	高血压	糖尿病	恶性肿瘤	冠心病	慢性心力衰竭	COPD	支气管扩张	慢性肾脏疾病	肝硬化
老年组	274	96(35.04)	56(20.44)	29(10.58)	33(12.04)	27(9.85)	43(15.69)	14(5.11)	34(12.41)	3(1.09)
非老年组	126	28(22.22)	11(8.73)	10(7.94)	2(1.59)	1(0.79)	3(2.38)	4(3.17)	7(5.56)	1(0.79)
t/χ²值		6.626	8.484	0.687	11.819	10.884	15.029	0.752	4.406	0.079
P值		0.010	0.004	0.407	0.001	0.001	<0.01	0.386	0.036	0.779

组别	例数	高血压	糖尿病	恶性肿瘤	冠心病	慢性心力衰竭	COPD	支气管扩张	慢性肾脏疾病	肝硬化
老年组	274	96(35.04)	56(20.44)	29(10.58)	33(12.04)	27(9.85)	43(15.69)	14(5.11)	34(12.41)	3(1.09)
非老年组	126	28(22.22)	11(8.73)	10(7.94)	2(1.59)	1(0.79)	3(2.38)	4(3.17)	7(5.56)	1(0.79)
t/χ²值		6.626	8.484	0.687	11.819	10.884	15.029	0.752	4.406	0.079
P值		0.010	0.004	0.407	0.001	0.001	<0.01	0.386	0.036	0.779

组别	例数	细菌	真菌	流感病毒	非流感病毒	支原体	未检出
老年组	274	79(28.83)	52(18.98)	18(6.57)	13(4.74)	18(6.57)	138(50.36)
非老年组	126	24(19.51)	8(6.35)	16(12.70)	6(4.76)	7(5.56)	58(46.03)
t/χ²值		4.322	10.796	4.169	0.000	0.151	0.649
P值		0.038	0.001	0.041	0.994	0.697	0.421